This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Radicava ORS (edaravone)
General Description:
Radicava ORS (edaravone) is an oral medication approved for the treatment of patients with amyotrophic lateral sclerosis (ALS).
Edaravone acts as a free radical scavenger, reducing oxidative stress in motor neurons. By neutralizing harmful free radicals, it helps slow the progression of neuronal damage in ALS, providing patients with a therapeutic option to manage disease progression.
Disease Indications:
Amyotrophic Lateral Sclerosis (ALS)
Manufacturer:
Mitsubishi Tanabe Pharma Co., Ltd.
Usage:
Oral
Medicine Approved by:
• Food and Drug Administration (FDA)
• Health Canada
Package:
• Starter Kit: 1 bottle of 35 mL (105 mg/5 mL dose) including oral dosing syringes and bottle adapter
• Kit: 1 bottle of 50 mL (105 mg/5 mL dose) including oral dosing syringes and bottle adapter
Shipping:
Cold Chain Shipping
Radicava ORS contains ingredients that are sensitive to heat, light, and handling. To maintain stability and efficacy, the medication is transported under cold chain conditions, using specialized medical couriers with temperature-controlled boxes and vehicles.
Although cold chain shipping can be more expensive than standard shipping, it ensures that Radicava ORS arrives uncompromised, safe, and fully effective for patient use.
How to Access Radicava ORS (edaravone) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Radicava ORS (edaravone) is not yet approved or commercially available in India, MitoGENE can assist patients and healthcare providers in legally obtaining it through the Named Patient Program (NPP).
Here’s how the process works:
